Global Musculoskeletal Partnering Deals Directory 2021

·4 min read

Dublin, Jan. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Musculoskeletal Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

The Global Musculoskeletal Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals. The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthritis, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.

The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Report Scope

Global Musculoskeletal Partnering 2014 to 2021 includes:

  • Access to headline, upfront, milestone and royalty data

  • Access to hundreds of Musculoskeletal deal contract documents

  • Comprehensive access to over 600 Musculoskeletal deal records

  • The leading Musculoskeletal deals by value since 2014

  • Most active Musculoskeletal dealmakers since 2014

Available deals and contracts are listed by:

  • Headline value

  • Upfront payment value

  • Royalty rate value

  • Stage of development at signing

  • Deal component type

  • Technology type

  • Specific therapy indication

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are the sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Musculoskeletal dealmaking
2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 - Financial deal terms for Musculoskeletal partnering
3.1. Introduction
3.2. Disclosed financials terms for Musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates

Chapter 4 - Leading Musculoskeletal deals and dealmakers
4.1. Introduction
4.2. Most active in Musculoskeletal partnering
4.3. List of most active dealmakers in Musculoskeletal
4.4. Top Musculoskeletal deals by value

Chapter 5 - Musculoskeletal contract document directory
5.1. Introduction
5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 - Musculoskeletal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Musculoskeletal therapeutic target

Appendices
Appendix 1 - Directory of Musculoskeletal deals by company A-Z since 2014
Appendix 2 - Directory of Musculoskeletal deals by deal type since 2014
Appendix 3 - Directory of Musculoskeletal deals by stage of development since 2014
Appendix 4 - Directory of Musculoskeletal deals by technology type since 2014

Companies Mentioned

  • Integra LifeSciences

  • UBMD Orthopaedics

  • MedShape

  • BioPharma Forest

  • Kitov Pharma

  • National Stem Cell Foundation

  • Orthocell

  • Imcyse

  • Gebro Pharma

  • RMX Biopharma

  • Burke Therapeutics

  • Feinstein Institute for Medical Research

  • San Diego

  • Amneal Pharmaceuticals

  • Boehringer Ingelheim

  • Genome Canada

  • KFx Medical

  • Collplant

  • Audentes Therapeutics

  • Level Brands

  • Mereo BioPharma

  • Lima Corporate

  • Atlangram

  • Bill and Melinda Gates Foundation

  • University of California San Francisco

  • Azellon Cell Therapeutics

  • G3 Therapeutics

  • Zoetis

  • AstraZeneca

  • CrystalGenomics

  • Human Metabolome Technologies

  • Fulcrum Therapeutics

  • Europe Technologies

  • Graviton Bioscience

  • Myomo

  • Technology Consult Berlin

  • Moberg Pharma

  • GetHealthy

  • Hikma Pharmaceuticals

  • Children's Hospital Boston

  • CurveBeam

  • National Institutes of Health

  • Cumberland Pharmaceuticals

  • Hadasit Medical Research Services and Development

  • Cell Therapy Catapult

  • Huntsworth Health

  • Unilife

  • Ethos Research & Development

  • Control Bionics

  • Landsteiner Scientific

For more information about this report visit https://www.researchandmarkets.com/r/tl1epy


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting